Clinical effect of Tianmai Xiaoke Tablet combined with Sitagliptin and metformin in the treatment of newly diagnosed obese type 2 diabetes
Objective:Objective To observe the clinical effect of Tianmai Xiaoke tablet combined with sitagliptin and metformin in the treatment of newly obese patients with type 2 diabetes.Methods:98 newly diagnosed obese patients with type 2 diabetes admitted to our hospital from June 2020 to June 2023 were selected as the study objects.Patients were divided into control group(n=48)and experimental group(n=50)by random number table method.The control group was treated with sitagliptin and metformin,and the experimental group was treated with Tianmai Xiaoke tablet on the basis of control group.The efficacy,blood glucose and obesity related indexes and adverse reactions of the two groups were analyzed and compared.Results:The total effective rate of experimental group was higher than that of control group(P<0.05).Before treatment,Fasting blood glucose(FPG),2-hour postprandial blood glucose(2h PG)and Glycosylated hemoglobin(Glycosylated hemoglobin)were measured in both groups.There were no significant differences in blood glucose indexes(Hb A1c),Body mass and Body mass index(BMI),Waist circumference(WC),Body fat rate(BF)and other obesity-related indexes(P>0.05).After treatment,FPG,2 h PG,Hb A1c,body mass,BMI,WC,BF and other indexes of both groups were significantly decreased,and FPG,2 h PG,Hb A1c,body mass,BMI,WC,BF and other indexes of test group were significantly lower than those of control group after treatment(P<0.05).There was no significant difference in the adverse reaction rate between the experimental group(0.00%)and the control group(4.17%)(P>0.05).Conclusion:Tianmai Xiaoke tablet combined with sitagliptin and metformin in the treatment of newly obese patients with type 2 diabetes can improve the therapeutic effect,reduce blood sugar and obesity symptoms,and have fewer adverse reactions.
Newly obese type 2 diabetes mellitusMetforminSitagliptinTianmai Xiaoke tablet
NETL
NSTL
万方数据
维普
